NOXOPHARM-LIMITED
18.3.2021 13:02:04 CET | Business Wire | Press release
Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announced that Veyonda has been approved to move into the second and final stage of the NOXCOVID-1 clinical trial on the advice of the study’s clinicians.
Part 1 of the NOXCOVID-1 trial involved 26 patients and was a dose-escalation arm testing the safety of increasing (400, 600, 800, 1200, 1800 mg) daily Veyonda dosages. The 1800 mg dose was deemed to be sufficiently well tolerated in patients with moderate COVID-19 disease to become the preferred dose. The high tolerance of the drug by patients with very poor lung function provides further evidence of the safety of Veyonda in patients with acute illness.
Noxopharm CEO Dr. Graham Kelly said, “The high potency of Veyonda in blocking cytokine release from damaged tissue in the laboratory meant we were obliged to adopt a very cautious and methodical approach when being used for the first time in patients with poor lung function. We can now be confident that Veyonda, despite its potency, is well tolerated at a dosage we believe will be therapeutic.”
Part 2 of the NOXCOVID-1 trial now is starting to recruit a minimum of 10 and up to 15 patients with moderate-to-severe lung dysfunction. Patients will be treated for up to 14 days with an 1800 mg Veyonda dose each day.
Noxopharm is committed to pursuing its NOXCOVID program for two main reasons: Despite the advent of COVID-19 vaccines, emerging news of new mutant strains of the virus points to a likely ongoing long-term need for effective treatments for COVID-19 patients who go on to develop long-term lung damage and are at high risk of septic shock.
The current pandemic represents a small proportion of patients who die each year from septic shock. Even once the pandemic abates, the need for an effective and safe ongoing treatment for septic shock will remain.
About Noxopharm
Noxopharm is a clinical-stage Australian oncology drug development company with offices in Sydney and New York. The company has a primary focus on the development of Veyonda and is the major shareholder in the nononcology drug development company, Nyrada Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210318005035/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Verimatrix ReAccess Earns Gold 2026 Merit Award for Telecom & Wireless2.3.2026 17:50:00 CET | Press release
Regulatory News: Verimatrix (Euronext Paris: VMX), a leading provider of security solutions for a safer connected world, today announced that its Verimatrix ReAccess solution was honored with a gold 2026 Merit Award for Telecom & Wireless. The industry accolade recognizes the company’s next-generation content security solution that modernizes legacy Conditional Access Systems (CAS) across DVB, IPTV and OTT networks without requiring costly hardware replacements or field service interventions. Judged by industry executives, media professionals and technology consultants, the Merit Awards evaluate submissions from across the telecommunications landscape. Verimatrix ReAccess enables secure, over-the-air (OTA) software updates to deployed set-top boxes (STBs), delivering operator cost savings, reduced operational complexity, and ongoing protection against piracy. It also empowers operators to continuously strengthen content security, eliminating the need for costly hardware replacements. U
Textron Aviation Launches Donation Campaign to Support 2026 Special Olympics Airlift; Continues Nationwide Call for Volunteer Doves2.3.2026 17:00:00 CET | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced the launch of a donation campaign benefitting Special Olympics in support of the 2026 Special Olympics Airlift, a nationwide effort that brings athletes and coaches to the Special Olympics USA Games through the generosity of volunteer pilots, aircraft owners and operators known as Doves. Financial contributions go directly to the Special Olympics, a 501(c)(3) charitable organization. New for the 2026 event, the donation campaign serves a vital role in ensuring each delegation has what it needs for a smooth and welcoming travel experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260302196418/en/ Textron Aviation launches donation campaign to support 2026 Special Olympics Airlift; continues nationwide call for volunteer Doves (Photo credit: Textron Aviation). “This campaign reflects the spirit of unity and generosity that defines the Special Olym
Forrester Announces The Agenda For Its 2026 CX Events To Help Address The Challenges AI Can’t Handle Alone2.3.2026 15:30:00 CET | Press release
The global event series will bring together customer experience, marketing, and digital business leaders at CX Forum East, CX Forum West, and CX Summit EMEA Forrester (Nasdaq: FORR) today announced the agenda for its global customer experience (CX) event series: CX Summit EMEA, being held in Amsterdam, June 8–10, 2026; CX Forum East, being held in New York City, June 16–17, 2026; and CX Forum West, being held in San Francisco, June 29–30, 2026. Today, CX, marketing, and digital business leaders are under mounting pressure to leverage AI to architect smarter end-to-end customer journeys, automate service, operationalize AI agents, and deliver true personalization at scale — all while consumer trust is at an all-time low. While AI is promising to raise the bar for speed and efficiency, beneath every customer experience is a foundation that AI alone can’t build. To forge trust, organizations need to embed human creativity, context, customer identity, and quality data into every customer i
Incode First to Achieve iBeta’s Highest Level of Independent Identity Security Testing on Both iOS and Android With 0% Error Rate2.3.2026 15:00:00 CET | Press release
Records 0% APCER and 0% BPCER under ISO/IEC 30107-3 Level 3 testing - delivered through a fully passive single-selfie experience Incode Technologies, Inc., the global leader in identity security and fraud prevention, today announced that iBeta PAD testing confirmed Incode’s face liveness technology achieves Level 3 Presentation Attack Detection (PAD) conformance under ISO/IEC 30107-3. "We are the first company to independently achieve iBeta Level 3 conformance on both iOS and Android – with zero errors and without adding friction to users," said Ricardo Amper, Founder & CEO at Incode. "That combination matters. It proves we can meet the highest bar for liveness assurance while keeping onboarding fast and easy, even in regulated and high-risk environments." Face liveness technology is used in digital onboarding and authentication to confirm a real, live person is present during a selfie capture – not a printed photo, video replay, mask, or other spoofing attempt. It enables organization
Safe Software Expands its FME Platform with MCP2.3.2026 15:00:00 CET | Press release
FME embraces MCP in two ways: connecting to more systems than ever, while bringing the power of AI to its entire data ecosystem Today, Safe Software (Safe), the creator of FME, the only All-Data, Any-AI enterprise integration platform with true support for spatial data, announced that Model Context Protocol (MCP) capabilities are coming soon to its FME Platform. This update expands what organizations can do with their existing data and workflows. As organizations move AI from experimentation to production they face growing challenges around context management, interoperability, and security. MCP provides a standardized way for AI, agents and other systems to interact with external systems, such as databases, internal tools, and APIs, without hard-coding integrations. “Adding MCP to the FME Platform is an important step in our All-Data, Any-AI mission,” said Don Murray, CEO of Safe Software. “With MCP, our customers can adopt new AI models without rebuilding integrations. By extending F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom